PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, E.H. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Kwak, G. | - |
dc.contributor.author | Jang, H. | - |
dc.contributor.author | Kim, H. | - |
dc.contributor.author | Cho, H. | - |
dc.contributor.author | Jang, Y. | - |
dc.contributor.author | Choi, J. | - |
dc.contributor.author | Chi, S.-G. | - |
dc.contributor.author | Kim, K. | - |
dc.contributor.author | Kwon, I.C. | - |
dc.contributor.author | Yang, Y. | - |
dc.contributor.author | Kim, S.H. | - |
dc.date.accessioned | 2022-04-12T23:41:55Z | - |
dc.date.available | 2022-04-12T23:41:55Z | - |
dc.date.created | 2022-04-12 | - |
dc.date.issued | 2022-05 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/140178 | - |
dc.description.abstract | Upregulation of oncogenic miRNA21 (miR-21) plays a pivotal role in proliferation, migration and invasion of cancer cells. In addition to cancer cells, tumor-associated macrophages (TAMs) also have high abundance of miR-21, which accelerates malignant progression of tumors in the late stages of carcinogenesis. Despite of the pro-tumorigenic functions of miR-21 in TAMs and cancer cells, reliable therapeutic strategies to simultaneously inhibit miR-21 activity in both types of cell have not yet been developed. In this study, we designed a dual-targeting drug delivery system of miR-21 inhibitors that could bind to both tumor cells and macrophages with overexpressed PD-L1 receptors. This peptide-oligonucleotide conjugate (Pep-21) consists of a PDL1-binding peptide covalently linked with an anti-miR-21 inhibitor via click chemistry. Pep-21 was preferentially internalized in both cell types, consequently depleting endogenous miR-21. Our studies found that Pep-21 treatment reduced tumor cell migration, reprogrammed immunosuppressive M2-type TAMs into M1-type macrophages, and restrained tumor progression. Collectively, neutralization of miR-21 activity in both cancer cells and TAMs can be a promising strategy for effective antitumor responses. © 2022 Elsevier B.V. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Elsevier B.V. | - |
dc.title | PDL1-binding peptide/anti-miRNA21 conjugate as a therapeutic modality for PD-L1high tumors and TAMs | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Chi, S.-G. | - |
dc.identifier.doi | 10.1016/j.jconrel.2022.02.031 | - |
dc.identifier.scopusid | 2-s2.0-85125879435 | - |
dc.identifier.wosid | 000783878100001 | - |
dc.identifier.bibliographicCitation | Journal of Controlled Release, v.345, pp.62 - 74 | - |
dc.relation.isPartOf | Journal of Controlled Release | - |
dc.citation.title | Journal of Controlled Release | - |
dc.citation.volume | 345 | - |
dc.citation.startPage | 62 | - |
dc.citation.endPage | 74 | - |
dc.type.rims | ART | - |
dc.type.docType | Editorial Material | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | MICRORNAS | - |
dc.subject.keywordPlus | OLIGONUCLEOTIDES | - |
dc.subject.keywordAuthor | anti-miRNA delivery | - |
dc.subject.keywordAuthor | B16 melanoma | - |
dc.subject.keywordAuthor | miR-21 | - |
dc.subject.keywordAuthor | PD-L1 | - |
dc.subject.keywordAuthor | Tumor-associated macrophage | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.